Brandon Scalea

Articles

Surgery Still Mainstay in Advanced Ovarian Cancer

April 3rd 2019

Mario M. Leitao, Jr, MD, FACOG, FACS, Leitao highlights the decision-making process for the placement of surgery in patients with newly diagnosed advanced ovarian cancer, as well as the use of hyperthermic intraperitoneal chemotherapy.

Therapeutic Options Available for Pancreatic Cancer, HCC Lead to New Challenges

April 3rd 2019

Jimmy J. Hwang, MD, sheds light on updates in both metastatic pancreatic cancer and advanced hepatocellular carcinoma that have created new complexities for researchers.

Higano Examines Emerging Role of PARP Inhibitors in mCRPC

April 2nd 2019

Celestia Higano, MD, FACP, discusses the potential for PARP inhibitors in patients with metastatic castration-resistant prostate cancer, as well as the role of darolutamide in nonmetastatic disease.

Levy Lends Insight on Promise of Checkpoint Inhibitors in SCLC

March 27th 2019

Benjamin P. Levy, MD, discusses the rise of checkpoint inhibitors in small cell lung cancer, an emerging targeted agent in non–small cell lung cancer, and the road that lies ahead in the overall landscape.

Progress Continues in HR+/HER2- Breast Cancer Paradigm

March 26th 2019

Kristin J. Richardson, MD, highlights advances made with CDK4/6 inhibitors in the treatment of patients with hormone receptor-positive metastatic breast cancer and forecasts where treatment is headed in this space.

CAR T Cells Bring Promise to Patients With ALL, DLBCL With Poor Prognosis

March 26th 2019

Lazaros J. Lekakis, MD, discusses the promise of CAR T cells and some unanswered questions with this rapidly emerging therapy.

Moskowitz Weighs Benefits, Challenges With A+AVD in Hodgkin Lymphoma

March 25th 2019

Craig Moskowitz, MD, discusses the role of PET imaging in the treatment of patients with Hodgkin lymphoma, weighs the pros and cons of A+AVD, and speaks to where future research is headed in the space.

Exploring the Role of Cytoreductive Nephrectomy in RCC

March 22nd 2019

Brian M. Shuch, MD, highlights the complex data with cytoreductive nephrectomy in renal cell carcinoma and offers advice on how to navigate the intricate treatment landscape.

Hurvitz Highlights Emerging Agents for Heavily Pretreated HER2+ Breast Cancer

March 21st 2019

Sara A. Hurvitz, MD, discusses recent updates in the paradigm and promising therapeutic strategies on the horizon for patients with HER2-positive metastatic breast cancer.

GI Oncologist Sheds Light on Present and Future of mCRC Treatment

March 21st 2019

Amit Mahipal, MBBS, discusses navigating the complex treatment paradigm of metastatic colorectal cancer and sheds light on how recent advances are impacting the outlook of those affected by the disease.

Sznol Highlights Immunotherapy Advances in RCC

March 20th 2019

Mario Sznol, MD, highlights recent advances made with immunotherapy in renal cell carcinoma and sheds light on what the future may hold.

Immunotherapy Combos May Mark Future of Gastric Cancer Care

March 20th 2019

Rutika Mehta, MD, MPH, discusses the current gastric cancer treatment landscape and sheds light on how emerging therapies could impact the paradigm.

Rini Discusses Future of Tivozanib, TKI/Immunotherapy Combos in mRCC

March 19th 2019

Brian I. Rini, MD, discusses the next steps with tivozanib (Fotivda) and immunotherapy/TKI combinations in patients with metastatic renal cell carcinoma.

Allogeneic HSCT Retains Role in Relapsed Myeloma

March 15th 2019

Sergio A. Giralt, MD, discusses recent data with allogeneic hematopoietic stem cell therapy and why this long-standing modality remains an integral part of treatment for patients with relapsed myeloma.

Despite Progress, Somatostatin Analogs Remain Frontline Standard in NETs

March 13th 2019

Jonathan R. Strosberg, MD, sheds light on the latest developments made in the complex treatment paradigm of gastroenteropancreatic neuroendocrine tumors.

Rizvi Highlights Impact of Immunotherapy and Next Steps NSCLC

March 12th 2019

Naiyer A. Rizvi, MD, highlights the progress made with immunotherapy in patients with NSCLC and shed light on where further research needs to go to move the needle forward.

Expert Highlights Evidence-Based Decision-Making in mCRC

March 11th 2019

Michael S. Lee, MD, sheds light on the treatment options available in the metastatic colorectal cancer space and highlights strategies poised to improve patient outcomes.

Strickler Stresses Continued Focus on Molecular Subtypes in mCRC

March 9th 2019

John Strickler, MD, highlights important data in the metastatic colorectal cancer space and challenges that remain for oncologists working in the field.

Posadas Breaks Down Rapidly Evolving Prostate Cancer Paradigm

March 8th 2019

Edwin M. Posadas, MD, FACP, discusses recent prostate cancer data and sheds light on where emerging therapies may fit into this landscape.

Therapeutic Breakthroughs in AML Lead to Improvements in OS Outcomes

March 7th 2019

Naval G. Daver, MD, stresses the importance of minimal residual disease testing, and highlights where research in the field is heading in order to achieve a higher cure rate in acute myeloid leukemia.